Trial record 2 of 9 for:    cardiox

Cardiox Liver Function Test Pivotal Trial (LFT-0002)

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by (Responsible Party):
Cardiox Corporation
ClinicalTrials.gov Identifier:
NCT02552901
First received: September 15, 2015
Last updated: January 14, 2016
Last verified: January 2016
  Purpose
Performance evaluation of LFT Dye Monitor System using ICG - plasma disappearance rate value (PDR) to assess liver function in normal patients as well as in patients with mild to severe hepatic impairment compared to manual Serum ICG PDR.

Condition Intervention Phase
Hepatic Failure
Liver Failure
Drug: 0.1 mg/kg ICG Dose
Drug: 0.5 mg/kg ICG dose
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: A Pivotal, Within Subject, Comparison of the LFT™ Dye Monitor System to the Indocyanine Green Dye (ICG) Serial Blood Plasma Disappearance Rate in Patients With Impaired and Non-Impaired Hepatic Function

Resource links provided by NLM:


Further study details as provided by Cardiox Corporation:

Primary Outcome Measures:
  • plasma disappearance rate [ Time Frame: Study Day 1 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • physical examinations [ Time Frame: Study Day 1 ] [ Designated as safety issue: Yes ]
  • vital signs [ Time Frame: Study Day 1 ] [ Designated as safety issue: Yes ]
  • adverse events [ Time Frame: Study Day 1 ] [ Designated as safety issue: Yes ]

Enrollment: 0
Study Start Date: November 2015
Estimated Study Completion Date: May 2016
Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LFT Dye Detection Monitor Drug: 0.1 mg/kg ICG Dose
least efficacious dose
Other Name: LFT Dose
Drug: 0.5 mg/kg ICG dose
per package insert
Active Comparator: Serial Blood Draws Drug: 0.5 mg/kg ICG dose
per package insert

Detailed Description:

Indocyanine green (ICG) is a water-soluble, non-toxic tricarbocyanine dye, extracted principally by hepatic parenchymal cells and excreted almost entirely into the bile without enterohepatic circulation. Clinically, its elimination rate is used primarily to measure hepatic function and liver blood flow. ICG studies are also used in ophthalmic angiography and the determination of cardiac output.

Beginning about 1959, the first human clinical studies were reported wherein an indocyanine green (ICG) bolus was injected into a vein, and then blood samples were withdrawn over a period of time and analyzed for ICG concentrations. This method is referred to hereinafter as the serial blood sampling method. These blood samples are sent to a clinical laboratory for a multi-step process of centrifuging, separation and spectrophotometric measurements of ICG levels. The laboratory-based measured levels of residual ICG levels are then used to determine the ICG clearance rate and R15 value or residual amount of dye remaining after 15 minutes, expressed as a percentage of the initial concentration.

As an alternative to the time- and labor-consuming serial blood sampling method, a non-invasive technique was first reported nearly 20 years ago. In the first published clinical study, Ishigami reported the use of a pulse dye densitometry (PDD) method to transcutaneously detect the rate of clearance of ICG from the bloodstream to be referred to hereinafter as dynamic liver function testing.

PDD expresses ICG elimination in terms of the indocyanine green plasma disappearance rate because only relative ICG concentration changes are assessed. The results of this noninvasive method have been shown to correlate with those obtained by the invasive method used in critically ill patients (hemodynamically unstable and stable), and in patients after liver surgery.

ICG elimination rate after liver transplantation measured by either invasive or noninvasive ICG methods is widely used to evaluate graft function. Studies have shown that ICG elimination, measured on the day of transplantation, reflects graft function and can be used to predict graft viability and the expected survival of the patient. Sequential measurements of ICG elimination between days 0 and 28 of transplantation, have been shown to predict clinical outcome in the early postoperative period after living donor transplantation. All of the studies have shown that the ICG elimination rate is an accurate test for evaluating liver dysfunction, but lacks the ability to differentiate the underlying causes of the hepatic dysfunction.

Unlike all currently existing PDD methods for performing liver function testing, LFT Dye Monitor System employs a more sensitive method for the transcutaneous measurement of ICG concentration level in the blood using NIR fluorescence, with a sensor that is attached loosely to the scaphoid fossa of the ear. Thus, the chemical properties of ICG dye to fluoresce when properly excited are used in the LFT system to enable much lower concentrations of ICG to be detectable.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male or female between 18 to 75 years of age inclusive, at the time of Screening.
  2. Voluntarily provide written informed consent.
  3. Female patients are eligible only if all of the following apply:

    • Not pregnant (negative urine pregnancy test at the Screening visit);
    • Not lactating;
    • Not planning to become pregnant within the duration of the study;
    • Surgically sterile, or at least 2 years postmenopausal, or is practicing an acceptable form of birth control (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, subdermal implant, oral contraceptives, abstinence, or sterilization of monogamous partner) for greater than 60 days prior to Screening and commits to the use of the acceptable form of birth control for the duration of the study.
  4. If a healthy volunteer; is considered to be in generally good health, in the opinion of the Investigator, at the Screening visit based upon the results of their medical and surgical history, vital signs, physical examination, and clinical laboratory tests.
  5. Prior to receiving any ICG injections the subject agrees to be fasting for at least eight (8) hours.
  6. If a subject with liver cirrhosis; is considered to be in general satisfactory health, in the opinion of the Investigator (other than their hepatic impairment) at the Screening visit based upon the results of their medical and surgical history, vital signs, physical examination, and non-hepatic clinical laboratory tests.
  7. Liver cirrhosis subjects must have a clinical diagnosis of hepatic impairment based on documented evidence of hepatic cirrhosis by medical history, or previous liver biopsy, or hepatic ultrasound; which conforms to the criteria for class A or B or C of the Childs-Pugh classification (Appendix B); and are expected to require an ICG liver function study, such as for liver transplantation, liver resection, liver cirrhosis prognosis evaluation, functional liver cell mass and/or general liver dysfunction evaluations.
  8. On stable drug therapy that is not expected to change (i.e. in dose, frequency, additions or deletions of agents) for at least 2 weeks before ICG dye injection.
  9. Must, in the Investigator's opinion, be able to comply with study procedures.
  10. If the Subject is being enrolled in the fifth group they have a diagnosis of acute liver failure (ALF) as defined by the Principal Investigator.

Exclusion Criteria:

  1. Have any clinically significant condition or unstable current illness that would, in the opinion of the Investigator, preclude study participation or interfere with the assessment of the procedure;
  2. Known allergy or sensitivity to ICG dye or history of allergy to iodides;
  3. Actively bleeding associated with acute blood volume changes.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02552901

Locations
United States, Ohio
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States, 43210
Sponsors and Collaborators
Cardiox Corporation
Investigators
Study Director: Michael Jopling, MD Medical Director, Cardiox Corporation
  More Information

Responsible Party: Cardiox Corporation
ClinicalTrials.gov Identifier: NCT02552901     History of Changes
Other Study ID Numbers: LFT-0002 
Study First Received: September 15, 2015
Last Updated: January 14, 2016
Health Authority: United States: Institutional Review Board

Keywords provided by Cardiox Corporation:
Cardiox
hepatic
liver
LFT
hepatic assessment
ICG dye
indocyanine green dye
Diagnostic Green
Pulsion
Akorn
anazen
essence
dye detection monitor
Earpads
flow sensor
scaphoid fossa
liver disease
acute hepatic failure
AHF
NASH
hepatitis C
cirrhosis
MELD
pulse dye densitometry
liver transplant
fluorescence
near infra-red
serial blood draws
PDR
plasma disappearance rate

Additional relevant MeSH terms:
Liver Failure
Hepatic Insufficiency
Liver Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on August 25, 2016